Procollagen type 1 amino-terminal propeptide: A marker for bone metastases in prostate carcinoma

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 671-673

  Klepzig, M ^a   Jonas, D ^a   Oremek, G M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

AP; Bone metastases; P1NP; Prostate carcinoma; PSA; Tumour marker

Indexed keywords

ALKALINE PHOSPHATASE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RELIABILITY;

AGED; BONE NEOPLASMS; HUMANS; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 61449228550     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. American Cancer Society: Cancer Facts and Figures 2007. American Cancer Society, Atlanta, 2007.
2. Coleman RE: Skeletal complications of malignancy. Cancer 80: 1588-1594, 1997.
3. Lipton A, Costa L, Ali SM and Deniers LM: Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27: 181-185, 2001.
4. Jung K, Lein M, Stephan C, von Hösslin K, Semjonow A, Sinha P, Loening S and Schnorr D: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783-791, 2004.
5. Oesterling JE, Martin SK, Bergstralh EJ and Lowe FC: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60, 1993.
6. Kratochwil C: Wertigkeit bildgebender Verfahren bei ossären Metastasen. Urologe 46: 891-896, 2007.
7. Seibel MJ and Woitge HW: Basic principles and clinical applications of biochemical markers of bone metabolism. J Clin Densitom 2(3): 299-321, 1999.
8. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Silva L and Chirgwin JM: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12: 6213-6216, 2006.
9. Seregni E, Martinetti A, Ferrari L and Bombardieri E: Clinical utility of biochemical markers of bone remodelling in patients with bone métastases of solid tumors. Q J Nucl Med 45: 7-17, 2001.
10. Lüftner D, Jozereau D, Schildhauer S, Geppert T, Müller C, Fiolka G, Wernecke KD and Possinger K: P1NP as serum marker of metastatic spread to bone in breast cancer patients. Anticancer Res 25: 1491-1500, 2005.
11. Thurairaja R, Des RK, Jefferson K, McFarlane JP and Persad RA: Serum amino-terminal propeptide of type I procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 76: 67-71, 2006.
12. Wymenga LF, Boomsma JH, Groenier K, Piers DA and Mensink HJ: Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkahne phosphatase. BJU Int 88: 226-230, 2001.
13. Noguchi M, Yahara J and Noda S: Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61: 993-998, 2003.
14. Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, Ciardi L, Sacchetti GM and Inglese E: The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate-cancer. Eur J Nucl Med 22: 207-211, 1995.
15. Koizumi M, Yonese J, Fukui I and Ogata E: The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87: 348-351, 2001.
16. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiébaud D, Ludwig H and Seibel MJ: The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97-103, 1995.
17. De la Piedra C, Castro-Errecaborde NA, Traba LM, Méndez- Dávila C, García-Moreno C, Rodriguez de Acuña L and Rodriguez-Molina J: Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331: 45-53, 2003.